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Abstract 
In the last 50 years we have experienced two big pandemics, the HIV pandemic and the pandemic caused 
by SARS-CoV-2. 
Both pandemics are caused by RNA viruses and have reached us from animals. These two viruses are 
different in the transmission mode and in the symptoms they generate. However, they have important 
similarities: the fear in the population, increase in proinflammatory cytokines that generate intestinal 
microbiota modifications or NETosis production by polymorphonuclear neutrophils, among others. 
They have been implicated in the clinical, prognostic and therapeutic attitudes. 
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Introduction 
In the last 50 years, we have experienced two 
pandemics, the human immunodeficiency virus (HIV) 
and the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infections. 
Both are caused by natural viruses that have 
reached us from animals [1-3]. Although these two 
viruses are different in the transmission mode and in 
the symptoms they generate, they have important 
similarities between them. 
HIV infection was discovered in the 80s (1981), 
when the first cases were known in young adults in 
California. It is believed that HIV spread to humans 
through direct contact with the infected blood of 
chimpanzees by hunting them for their meat. They 
were affected by severe pneumonia caused by 
Pneumocystis jiroveci or with Kaposi’s sarcoma. The 
transmission mechanism was sexual contact, drugs 
injection, blood transfusions and mother-to-child. A 
social stigma was generated. HIV spread rapidly 
throughout the world and the death rate was almost 
100% [4]. 
The first isolation of HIV-1 was achieved in 1983 
by Barré-Sinoussi and collaborators at the Pasteur 
Institute in Paris [5]. Since then, there has been a great 
advance in the knowledge of HIV, being one of the 
best-characterized known viruses, and a large amount 
of information has been accumulated about its 
biology, transmission and pathogenesis. 
Although there is no cure for HIV infection, 
effective antiretroviral therapy (ARTs) can control the 
virus and help prevent transmission to other people. 
At the end of 2018, approximately 79% of people 
living with HIV knew their status, 62% were receiving 
antiretroviral therapy (ART) and 53% had achieved 
suppression of the HIV with no risk of infecting 
others. Between 2000 and 2018, new HIV infections 
fell by 37% and HIV-related deaths fell by 45%, with 
13.6 million lives saved due to ART [4]. 
In the case of SARS-CoV-2, the first cases 
appeared in December 2019 in Wuhan, in the Chinese 
province of Hubei. There were 41 cases of people with 
pneumonia, 66% of which had direct exposure in a 
seafood market where all kinds of meat and fish were 
sold, so it is thought that the origin might be there. 
The first news were released in January 2020 when the 








showing that it was a new coronavirus belonging to 
the same group as the coronavirus related to the 
severe acute respiratory syndrome (SARS-CoV) 
causing the outbreak from SARS 2003 [7-9]. 
On March 11th, when globally confirmed cases 
exceeded 118,000 and the number of deaths were 
4,291, the WHO characterized the SARS-CoV-2 
infection as a pandemic named COronaVIrus Disease 
19 (COVID-19) [4]. From that day on, most countries 
in the world have suffered the infection and it is not 
yet controlled. 
Material and methods 
This review provides a comprehensive overview 
of HIV and SARS-CoV-2 viruses similarities and 
differences. The data source was PubMed and the 
search terms and strategy were focused on the 
definition, epidemiology, transmission mechanism, 
symptomatology and finally treatment and vaccine 
development. The results are summarized in a 
narrative manner. 
Results and Discussion 
Human Immunodeficiency Virus (HIV) 
Definition 
HIV is a virus that belongs to the genus 
Lentivirus, subfamily Orthoretrovirinae, family 
Retroviridae. Two types have been identified, HIV-1 
and HIV-2 [10]. 
The HIV-1 virion is a spherical particle, with 
around 100 nm of diameter, that contains two copies 
of single-stranded RNA together with the enzymatic 
machinery (reverse transcriptase and integrase) 
implicated in its transformation from RNA to DNA in 
the cytoplasm of the host cell and the subsequent 
integration of this material into the cell genome 
(proviral DNA) [11]. The HIV-1 envelope is formed by 
viral gp41 and gp120 envelope glycoproteins, with 
ability to bind to the CD4 surface protein, present in 
certain cells, including T lymphocytes and 
mononuclear phagocytic cells. This union produces a 
conformational change in the viral glycoprotein that 
allows its subsequent interaction with one of the 
chemokine receptors (CCR5 and CXCR4), which act as 
co-receptors for the virus, allowing its entry into the 
cell. Once inside, it will use the enzyme reverse 
transcriptase to convert its RNA into DNA, which will 
be later transported to the nucleus and integrated into 
the cellular DNA. As mentioned above, HIV-1 infects 
immune system key cells, mainly CD4+ T helper 
lymphocytes. Consequently, there is a depression of 
the immune system. If this depression becomes 
chronic, the patient progresses to AIDS [12]. 
HIV epidemiology 
According to UNAIDS (United Nations on 
HIV/AIDS) in its most recent update in 2018, there 
are 37.9 million estimated individuals living with HIV 
all over the world. There are estimations that predict 
1.8 million of new HIV-1 infections each year. The 
results show that new infections (of all ages) 
decreased from a peak of 3.4 million in 1996 to 1.8 
million in 2017 [13]. From the start of the pandemic 
until 2018, 32 million people died from AIDS-related 
illnesses [13]. 
HIV transmission mechanism 
There are three transmission mechanisms of 
HIV-1 infection: sexual, parenteral and vertical [14]. 
HIV is found in blood, pre-seminal fluid, semen, 
vaginal fluids, and breast milk, and is transmitted 
through direct contact of these fluids with the mucosa 
or bloodstream of another person. 
According to the data available, in Spain, the 
most frequent transmission mechanism nowadays is 
sexual, mainly from men who have sexual relations 
with other men (approximately 54.3% of all new 
cases), followed by heterosexual transmission (28%) 
and injecting drug use (less than 3.1%) [12]. 
HIV symptomatology 
The symptoms generated by HIV infection begin 
to appear between 2 and 6 weeks after contact with 
the virus and can be divided into early infection 
(within the first two months after infection) or 
chronic. During the early or acute phase of infection, 
infected people present fever, headache, muscle pain, 
rashes, sore throat and mouth sores, and swollen 
lymph nodes. These symptoms can be so mild that are 
almost not noticed [5]. 
In the phase of chronic infection, the virus 
continues spreading and destroying immune cells, 
causing immunosuppression. Usually, if it is not 
treated, HIV turns into AIDS in an average of 10 years. 
When AIDS occurs, the immune system is already 
severely damaged, opportunistic infections, neuro-
degenerative diseases and cancers occur in infected 
individuals [5]. 
Treatment and vaccine development 
After the initial discovery of some drugs that had 
shown high toxicity and scarce benefit (zidovudine, 
didanosine, zalcitabine), in 1995 the discovery of a 
combination therapy, which initially included 
antiprotease drugs (indinavir, saquinavir) was such a 
change that it was possible to significantly reduce 
mortality. Antiretroviral therapies (ART) have 
tranformed HIV infection into a chronic disease [12]. 
After 2008, the emergence of new drugs, including 




integrase inhibitors, has led to significantly less 
toxicity and excellent tolerance [15]. 
However, HIV persists in the body due to the 
early establishment of reservoirs, which cannot be 
eliminated with any of the current antiretroviral 
regimens [16]. Reservoirs are defined as anatomical 
sites or cells in which HIV infection is persistent and 
stable allowing competent viruses to replicate under 
permissive conditions. 




SARS-CoV-2 is a β-coronavirus, from the 
sub-genus Sarbecovirus, subfamily Orthocoronavirinae. 
The size of the SARS-CoV-2 virion is approximately 
50 to 200 nm of diameter, and its genome is 
single-stranded positive-sense RNA. The complete 
genome of the SARS-CoV-2 virus has been sequenced, 
it has 29.2 kb [9], with a variable number between 6 
and 20 Open Reading Frames (ORFs) [17]. Two thirds 
of the viral RNA are found in the first ORF 
(ORF1a/b), which is translated into two structural 
proteins (pp1a and pp1ab) and 16 non-structural 
proteins (NSP), whereas the other ORFs encode 
accessory and structural proteins. The rest of the virus 
genome encodes four essential structural proteins, 
namely spike glycoprotein (S), small envelope (E), 
matrix (M) and nucleocapside (N) [18]. Additional 
accessory proteins interfere with the immune 
response of the host. 
Zhou et al. [3] confirmed that SARS-CoV-2 uses 
the ACE2 receptor to enter into the cells, just as 
SARS-CoV-1 does. This receptor is expressed in the 
lung, heart, blood vessels, intestine and kidneys [19]. 
The coronavirus membrane glycoprotein S is the one 
that binds to the ACE2 receptor on the surface of 
human cells [20]. The S glycoprotein has two subunits, 
namely S1 and S2 [21]. S1 determines the virus-host 
ratio and cell tropism with the key fusion domain, 
which is RBD, while S2 mediates the fusion of the 
virus cell membrane by two tandem domains: heptad 
repeats 1 (HR1) [22] and 2 (HR2) [23]. After the fusion 
virus-cell occurs, the virus genome is released into the 
cytoplasm and the RNA translates two polyproteins, 
pp1a and pp1ab [24], which encode non-structural 
proteins and form replication-transcription complexes 
(RTCs) in double-membrane vesicles [25]. RTCs 
replicate and synthesize sets of subgenomic RNAs 
[26] that encode for structural and accessory proteins. 
By using cellular endoplasmic reticulum and the 
Golgi, newly formed RNAs, nucleocapsid proteins, 
and envelope proteins bind and form new viral 
particles [27]. Finally, the vesicles containing the 
virions fuse with the cell membrane and the virus 
goes out to infect new cells. The difference with HIV is 
that SARS-CoV-2 does not integrate in the host DNA. 
The generation of antibodies 15 days after infection is 
100%, both in mild and severe cases [28-32]. 
SARS-CoV-2 epidemiology 
The situation of SARS-CoV-2 infection today, 
November 7th 2020, according to the WHO, is as 
follows: 48,534,508 confirmed cases worldwide with 
1,231,017 deaths since the start of the pandemic in 
December 2019. Currently, the continent with most 
cases is America with 21,168,405 confirmed cases and 
650,705 deaths. In Europe, the confirmed cases are 
12,490,012 with 303,707 deaths [4]. 
The mortality rate of SARS-CoV-2 (3.8%) is lower 
than that of SARS-CoV-1 or MERS-CoV (Middle East 
Respiratory Syndrome Coronavirus), whose rates 
were 10% and 37.1% respectively, but the number of 
cases of infection is 10 times higher. This is due to the 
fact that SARS-CoV-2 can be transmitted from people 
with no symptoms or with mild infections. These 
characteristics can explain the sudden pandemic 
spread of the virus [33]. In general the mortality rate is 
5% [34], being 49% in critical cases [35, 36]. 
SARS-CoV-2 transmission mechanism 
The virus is transmitted through the air, mainly 
due to small drops of saliva from infected people by 
coughing or sneezing that can reach two meters [37]. 
The transmission is also produced by direct contact 
with these secretions or by objects contaminated by 
them [4]. 
SARS-CoV-2 symptomatology 
The symptoms generated by SARS-CoV-2 begin 
to appear between 2 and 14 days after the contact with 
the virus. The most common symptoms include fever, 
cough, and dyspnea. Diarrhea and abdominal pain 
are also frequent. Although most cases have mild 
symptoms, in the most severe cases, the infection can 
cause pneumonia, severe difficulty breathing, kidney 
failure, and even death [38, 39]. 
Treatment and vaccine development 
COVID-19 treatment initially included drugs 
previously used in HIV treatment, such as lopinavir; 
subsequent studies demonstrated its lack of efficacy 
[40]. Moreover, as in the case of HIV infection, the first 
antiviral used (Remdesivir) has shown very limited 
efficacy [41, 42]. Apart from corticosteroids to 
decrease cytokine storm [43], there are no other useful 
drugs against SARS-CoV-2 infection. 
Many trials are being done to find a vaccine 
against SARS-CoV-2 [44], some of them with 
encouraging results in phase II. 




Differences between HIV-1 and SARS-CoV-2 
Table 1 shows a summary of the main 
differences described between both viruses. 
 
Table 1. Differences between HIV and SARS-CoV-2 
  HIV SARS-CoV-2 
Phylogenetically  Lentivirus β-coronavirus 
Transmission 
mechanism 
Sexual, parenteral and vertical 
direct contact. 
Air by small drops of 
saliva. 
Targets CD4 surface protein expressed 
in CD4+ T helper lymphocytes, 
macrophages, and dendritic 
cells. 
ACE2 receptor expressed 
in lung, heart, blood 
vessels, intestine, and 
kidney. 
Symptoms In early infection: flu-like 
and/or mononucleosis-like 
symptoms; in chronic infection: 
opportunistic entities; usually, if 
it is not treated, HIV turns into 
AIDS in about 10 years. 
Difficulty breathing and 
fever. In the most severe 
cases, the infection can 
cause pneumonia, severe 
difficulty breathing, 





Between 2 and 6 weeks after 
contact with the virus. 
Between 2 and 14 days 






 ≥95% 1-4% 
 
Similarities between both viruses 
Even though it may seem that these two viruses 
induced diseases are not very similar among them, 
they have some important points in common: 
(a) Fear in the population. HIV can affect anyone, 
independently of their social status, race, gender, etc. 
This can affect people psychologically, making them 
feel fear, stress or anxiety. Apart from those factors, in 
COVID-19, there are others that can make people feel 
this – the virus is new, there are not known effective 
antivirals, the disease is more contagious than 
expected, it can even severely affect young 
individuals with no previous pathologies, respiratory 
failure forces hospitalization for many days… In 
addition, the panic is even increased by the presence 
of the Internet, over-information, spreading of 
unfounded rumors, and hyper connectivity in our 
lives nowadays. 
(b) Existence of animal reservoirs. The existence 
of natural animal reservoirs is another point in 
common, although they are found in different 
animals, being non-human primates in the case of 
HIV, and bats in the case of SARS-CoV-2. 
(c) Increased synthesis of proinflammatory 
cytokines. Both viruses generate an increase in the 
production of cytokine, and this is linked to the viral 
load in the case of SARS-CoV-2. These cytokines are 
related with secondary complications in infected 
people. 
It is well known that in HIV infection, the 
cytokine release is a chronic mechanism that 
generates prolonged inflammation. Sustained 
inflammatory status has been related with increased 
intestinal permeability and bacterial translocation, 
detected in HIV-infected patients. Intestinal 
permeability, bacterial translocation or systemic 
inflammation cannot be reversed with antiretroviral 
therapies [45]. Residual viral replication and other 
co-infections also contribute to prolonged 
inflammatory status [45]. Serum levels of the pro-
inflammatory interleukin 6 has been independently 
associated to morbidity (cardiovascular disease, 
cancer, etc.) and mortality in patients with controlled 
HIV replication [46]. 
Regarding COVID-19, the cytokine secretion is 
an acute response and is implicated in clinical 
manifestations. Proinflammatory cytokines and 
chemokines attract more inflammatory cells to 
migrate from the blood, inducing an amplification of 
the deleterious response; in fact, a substantial part of 
the therapy is aimed at blocking pro-inflammatory 
cytokines [47]. Cytokine storm is implicated in the 
acute respiratory distress syndrome or multiple-organ 
dysfunction. Increased markers of systemic 
inflammation are prognostic variables in COVID-19 
[48]. 
(d) Modifications of the intestinal microbiota. It 
has been proved that patients infected with 
SARS-CoV-2 who develop cardiac complications have 
higher levels of intestinal permeability and activation 
of inflammasomes, suggesting a heart-intestine axis in 
COVID-19 [49]. In fact, one of the vaccines being 
developed is a genetically modified probiotic with a 
plasmid that contains the DNA of the SARS-CoV-2 
protein S (NCT04334980). 
HIV infection has an unfavorable effect on the 
interaction between the commensal microbiota and 
the immune system [50]. Microbiota modifications 
(increase in pro-inflammatory bacteria and a 
reduction in those that promote homeostasis) have 
been detected in HIV infected people with pathogenic 
consequences on bacterial translocation (see above) 
and immune responses [51-61]. It is important to 
mention that elite controllers have microbiomes more 
similar to those of healthy individuals than other 
groups of HIV-infected patients [62], and they also 
show lower levels of immune activation and HIV 
reservoirs [63]. 
(e) Neutrophil extracellular traps (NETs) 
formation. The two viruses share a mechanism known 
as NETosis. This is a neutrophil death mechanism in 
which neutrophils release nets of chromatin fibers 
into the extracellular space. Those nets contain 
histones, microbicidal peptides or oxidizing enzymes 
[64]. NETs are very adherent and capture extracellular 
microbes, such as some bacteria, fungi and virus, 




stimulating its removal [64-66]. Acute NETosis 
against infectious agents is an efficient defense 
mechanism that avoids collateral tissue damage, 
concentrating the antimicrobial action and reducing 
the toxicity attributable to the proteases. However, a 
chronic or acute aberrant NETosis may contribute to 
the pathology [67]. In HIV infection, NETosis has been 
suggested to be involved in the atherosclerosis 
development [66]. In COVID-19, the virus-induced 
NETs can circulate in an uncontrolled way, giving rise 
to an extreme systemic response of the body, 
increasing the concentrations of cytokines, 
chemokines and increasing inflammation. In addition 
to promoting the cytokine storm, NETs in COVID-19 
patients are also responsible for the thrombotic 
complications they present, as is the case in HIV 
patients [68]. 
Conclusion 
As a conclusion, we would like to point that 
although at first sight these viruses do not resemble 
each other, the molecular mechanisms used are 
common: the increased of pro-inflammatory cytokine 
synthesis, the modifications in intestinal microbiota, 
the NETs formation. Basic science has been trying to 
understand these mechanisms for years and the 
greater the knowledge, the lesser the damage to the 
population in this pandemic and in the future. 
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